Metachronous breast cancer in a BRCA1 mutation carrier

Breast cancer is the most common neoplasm among women in Poland and worldwide. Approximately 8000 die from breast each year. It second leading cause of cancer-related deaths Polish women, following lung cancer. This highly heterogeneous terms morphology as well molecular characteristics, it requires different therapeutic approaches. Several risk factors for have been identified, including genetic, environmental, individual factors. Mutations BRCA1 BRCA2 genes are best-known genetic responsible approximately 5–10% cases The developing bilateral patients with mutation significantly higher than general population. Furthermore, attention drawn to increased metachronous tumors a gene who previously had article presents case report on patient has developed bone liver metastases. Based test result showing mutation, was qualified talazoparib treatment.